Glioma tumors are refractory to conventional treatment. Glioblastoma multiforme is the most aggressive type of primary brain tumors in humans. In this study, we introduce oxidative stress-energy depletion (OSED) therapy as a new suggested treatment for glioblastoma. OSED utilizes D-amino acid oxidase (DAO), which is a promising therapeutic protein that induces oxidative stress and apoptosis through generating hydrogen peroxide (H 2 O 2 ). OSED combines DAO with 3-bromopyruvate (3BP), a hexokinase II (HK II) inhibitor that interferes with Warburg effect, a metabolic alteration of most tumor cells that is characterized by enhanced aerobic glycolysis. Our data revealed that 3BP induced depletion of energetic capabilities of glioma cells. 3BP induced H 2 O 2 production as a novel mechanism of its action. C6 glioma transfected with DAO and treated with D-serine together with 3BP-sensitized glioma cells to 3BP and decreased markedly proliferation, clonogenic power and viability in a three-dimensional tumor model with lesser effect on normal astrocytes. DAO gene therapy using atelocollagen as an in vivo transfection agent proved effective in a glioma tumor model in Sprague-Dawley (SD) rats, especially after combination with 3BP. OSED treatment was safe and tolerable in SD rats. OSED therapy may be a promising therapeutic modality for glioma.
Introduction
Malignant gliomas are among the most devastating cancers that lead to death in most cases. Glioblastoma multiforme (GBM; grade IV astrocytoma) is the most common aggressive glioma resistant to therapeutic interventions. 1 D-amino acid oxidase (DAO) is a flavoenzyme that catalyzes the oxidation of D-amino acids to the corresponding a-keto acids with the production of reactive oxygen species (ROS) in the form of hydrogen peroxide (H 2 O 2 ).
2 H 2 O 2 production is a natural defense used by cells of the immune system for microbicidal immunity. 3 For H 2 O 2 -generating property and the scarcity of D-amino acids in mammalian tissues, DAO seems to be an attractive therapeutic protein with an anticancer effect. 4 Hexokinase (HK) is an important enzyme of glycolysis. HK enzyme has four isoforms (I, II, III and IV). 5 HK II is a potential marker for malignancy in human gliomas. 6 In cancer cells, mitochondrial ATP production is about 40% and glycolytic ATP production is about 60%. 7 This is in sharp contrast to most normal cells where the mitochondria are responsible for more than 90% of ATP production. 8 This may be explained by the Warburg effect, which states that cancer cells increase their capacity to metabolize glucose to lactic acid with the production of ATP even in the presence of oxygen. 9 The Warburg effect is now considered a common property of cancer metabolism. The shift from oxidative phosphorylation to glycolysis occurs in solid tumors, including GBM, which develops resistance to cell death due to switch from mitochondrial oxidative phosphorylation to cytoplasmic glycolysis, leading to metabolic remodeling or adaptation in cancer cells, which is accompanied by mitochondrial hyperpolarization. 10 Glycolysis governs tumor cell biology, therapeutic response and increases tumor resistance to apoptotic stimuli as irradiation and chemotherapeutics. 11 In addition to that glycolysis provides reduced nicotinamide adenine dinucleotide (NADH) and precursors for purine nucleotide synthesis, which are critical requirements for cancer cell survival, division and proliferation. 12 Based on the fact that tumor cells are highly glycolytic and actively take up glucose, 18-fluoro-deoxy glucose positron emission tomography is widely used in the clinical diagnosis of cancer. 13 Decreased values of glucose metabolic rate in pediatric glioblastoma are highly consistent with the period of clinical relief.
14 Glucose metabolism in human malignant gliomas measured quantitatively with positron emission tomography exceeds that of normal contralateral brain. 15 This metabolic feature suggests that inhibition of glycolysis may severely abolish ATP generation in cancer cells and thus may preferentially kill the malignant cells. 16 In this study, we introduce oxidative stress-energy depletion (OSED) therapy that combines DAO-induced oxidative stress together with decreasing energy supply in tumor cells through the inhibition of glycolysis by the use of 3-bromopyruvate (3BP). C6 glioma cells were transfected with DAO gene as a gene-directed enzyme prodrug therapy. 4 
Materials and methods

Reagents
Agarose, 3BP, pyruvic acid, K 2 HPO 4 , sodium pyrophosphate, tris base, NaH 2 PO 4 Á 12H 2 O, diethylaminoethyl sepharose for column chromatography, fetal bovine serum (FBS), Dulbecco's modified Eagle's medium (DMEM) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylyltetrazolium bromide (MTT) were purchased from Sigma (St Louis, MO). DMEM/F12, Geniticin (G418) and penicillin-streptomycin antibiotic mixture were from Invitrogen Life Technologies (Carlsbad, CA). Precision Plus Proteint standard was from Bio-Rad Laboratories (Hercules, CA). N-acetyl-L-cysteine, reduced glutathione, tryptone, yeast extract, hydroxylapatite for column chromatography and KBr were from Nacalai Tesque (Kyoto, Japan). NaCl, glycerol, ampicillin powder, flavine adenine dinucleotide, phenylmethylsulfonylfluoride, dithiothreitol, isopropyl-b-D (À) thiogalactopyranoside, KCl, NaH 2 PO 4 Á 2H 2 O, D-serine and agar were from Wako (Osaka, Japan). EDTA was purchased from Dojindo Molecular Technologies (Kumamoto, Japan).
Cell culture C6 rat glioma cells (Dainippon Pharmaceutical, Osaka, Japan) were maintained in DMEM/F12 containing 15% (v v À1 ) horse serum, 2.5% (v v À1 ) FBS and 1% penicillinstreptomycin at 37 1C under a humidified atmosphere containing 5% CO 2 . A stable cell line overexpressing mouse DAO (C6/DAO) was established as reported previously. 17 C6/DAO cells were maintained in DMEM/ F12 containing 15% (v v À1 ) horse serum, 2.5% (v v À1 ) FBS and 1% penicillin-streptomycin with 250 mg ml À1 G418. Rat primary type-1 astrocytes were prepared as described previously.
18 Using 1-2 days old new born Sprague-Dawley rat cerebellum, cerebellar type-1 astrocytes were prepared in poly-D-lysine-coated culture flasks containing DMEM supplemented with 10% FBS. The culture was incubated for 10-14 days, and then astrocytes were subjected to shaking to separate the microglia. Cytosine arabinoside treatment was also carried out. ) solution was added and followed by incubation for an additional 3 h. After centrifugation, supernatant was removed from each well and 150 ml of dimethylsulfoxide was added to dissolve the insoluble formazan crystals. C6 and C6/DAO viability was tested 48 and 72 h after same treatment. For primary astrocytes, cells were seeded into 96-well plates (1 Â 10 4 cells per well) and received same treatment at 80% confluency. Viability of astrocytes was tested 24, 48 and 72 h after 3BP and D-serine treatment. The absorbance was measured at 550 nm using Infinitet M200 microplate reader.
Microscopic analysis C6 and C6/DAO cells were treated as mentioned above for 24 h, and then cellular morphology was examined using Nikon phase-contrast microscopy and images were captured using Nikon digital sight screen (Nikon, Tokyo, Japan).
H 2 O 2 assay
Using an Amplex s red kit (Molecular Probes) according to the manufacturer's instructions, C6 and C6/DAO cells were seeded at a density of 1 Â 10 4 cells per well into 96-well plates. After 36 h incubation, the medium was aspirated and cells were washed once in 50 ml of 1 Â phosphate-buffered saline solution, and then incubated for 1 h in a new medium containing 3BP and D-serine. Amplex s red reagent working reaction mixture was also added. Fluorescence was measured with Infinitet M200 microplate reader with excitation wavelength at 530 nm and detection wavelength at 590 nm. H 2 O 2 produced in nanomolar range was estimated quantitatively.
Antioxidants and pyruvate protection against 3BP treatment effects C6 and C6/DAO glioma cells were treated with N-acetyl-L-cysteine, pyruvate (glycolysis downstream product) and reduced glutathione. All were added together with 60 mM 3BP. Protection against 3BP treatment effects was estimated through viability levels in MTT assay.
ATP assay
Using ATP determination kit (Molecular Probes), ATP levels were determined in C6 and C6/DAO glioma after treatment with 3BP and D-serine according to the manufacturer's instructions. Briefly, C6 and C6/DAO cells were seeded at a density of 1 Â 10 4 cells per well into 96-well plates. After 24 h incubation, the medium was aspirated and fresh medium containing treatment was added for another 24 h. After medium aspiration, standard reaction solution was added and followed by the addition of ATP standard solution with protection from light. Using luminometer function of Infinitet M200 microplate reader, ATP levels were estimated in C6 and C6/DAO cells.
Measurement of reducing equivalents (NADH and NADPH) levels in C6 cells C6 glioma cells were treated for 3 h with 0, 60, 120 and 2400 mM 3BP. Reducing equivalents were measured using MTT reduction signals as reported previously. 19 Clonogenic assay C6 or C6/DAO cells (1 Â 10 3 cells per plate) were seeded per plate in 6 cm plates. Plates were shaken gently to distribute the cells evenly and separately. Plates were incubated in CO 2 incubator for 10 h, after which cells received 3BP and/or D-serine treatment. Cells were incubated in CO 2 incubator. Daily follow-up using Nikon phase-contrast light microscopy was carried out till colonies in control plates form 50 cells by the eighth day after treatment. The medium was removed and plates were rinsed in 1 Â phosphate-buffered saline and fixed with 100% methanol for 15 min. Plates were stained with 0.5% crystal violet in 2% ethanol for 30 min at room temperature. Crystal violet was removed carefully and plates were rinsed with water carefully and air-dried at room temperature. Plates were photographed by digital camera.
Anchorage-independent growth assay Under complete aseptic conditions, 0.5% agar in 1 ml distilled water was seeded per plate of six-well plates; 0.3% agarose in 1 ml distilled water containing C6 or C6/ DAO cells (2.5 Â 10 3 cells per well) in nutrient medium
) FBS and 1% penicillin-streptomycin) was added to each well over the agar layer. Plates were incubated at 37 1C in a humidified incubator for 10 h, and then 3BP and/or D-serine were added. Cells were fed every other day with fresh media containing treatment. Daily followup of colony formation in agarose top layer was carried out using Nikon phase-contrast light microscopy till day 28. Anchorage-independent growth inhibition was calculated according to the formula: inhibition power-100 Â (1À(colonies number in treated samples/colonies number in control samples)). 20 Annexin V-propidium iodide flow cytometry C6 and C6/DAO cells received treatment for 24 h. ApoAlertt Annexin V Apoptosis Kit (Clontech, Mountain View, CA) was used according to the manufacturer's instructions. Cells were rinsed with 500 ml of 1 Â binding buffer, centrifuged, resuspended in 200 ml of 1 Â binding buffer and centrifuged again. Then, 5 ml of Annexin V and 10 ml of propidium iodide were added. Cells were incubated at room temperature for 15 min in the dark. In all, 1 Â binding buffer (300 ml) was added to samples and flow cytometry analysis was carried out.
Establishment of an in vitro glioma tumor model
In vitro tumor models using C6 and C6/DAO glioma spheroids were established as reported previously. 21 Briefly, 1 Â 10 3 C6 or C6/DAO glioma cells were suspended in 200 ml nutrient medium. Glioma cells were seeded into 96-well plates previously coated with 1% agar layer and followed by incubation for 96 h. Half of the medium per well was replaced by the same amount of fresh nutrient medium containing treatment and followed by incubation for 72 h. For assaying spheroid viability after treatment, MTT (1 mg ml À1 ) solution was added and followed by incubation for an additional 3 h. After centrifugation, supernatant was aspirated slowly and carefully from each well (without disturbing spheroids) and 150 ml of dimethylsulfoxide was added to dissolve the insoluble formazan crystals. Infinitet M200 microplate reader was used to measure absorbance at 550 nm.
Purification of recombinant human DAO and preparation of DAO apoprotein Briefly, bacterial transformants expressing recombinant human DAO (rhDAO) (strain BL21/DE3) were grown in terrific broth supplemented with 0.5% (w v
À1
) glucose and 50 mg l À1 ampicillin at 37 1C until they reached an optical density of 0.6 at 600 nm, and then induced with 0.1 mM isopropyl-b-D (À) thiogalactopyranoside, as described previously. 22 Transformants were allowed to grow for 24 h. Bacterial cells were collected by centrifugation, and suspended in 10 ml g À1 lysis buffer (17 mM sodium pyrophosphate, pH 8.3, 100 mM flavine adenine dinucleotide, 1 mM sodium benzoate, 0.3 mM EDTA, 0.5 mM dithiothreitol and 4.5 mg ml À1 phenylmethylsulfonylfluoride). Cells were treated with lysozyme, followed by sonication. Heat treatment was applied to soluble fraction, followed by centrifugation and ammonium sulfate precipitation. Dialysis, centrifugation and diethylaminoethyl sepharose CL-6B column chromatography were applied to the supernatant. Yellow fractions that were supposed to contain the holoenzyme with flavine adenine dinucleotide were collected and precipitated by 70% ammonium sulfate, followed by dialysis, centrifugation and hydroxylapatite column chromatography. After that, sodium dodecyl sulfate-polyacrylamide gel electrophoresis was carried out using 20 mg of protein samples to confirm the purity of rhDAO holoenzyme.
Testing effect of 3BP on rhDAO activity Using an air-saturated polarographic Hansatech system (Hansatech Instruments, Norfolk, UK), the solution mixture to be monitored for dissolved oxygen was placed in the chamber exposed to the surface of DW1 oxygen electrode. D-Proline was added to 50 mM sodium pyrophosphate buffer, pH 8.3, containing 11 mM flavine adenine dinucleotide at 25 1C and air saturation. One unit corresponded to the amount of the enzyme that converts 1 mmol of substrate per min. The specific activity of the purified wild-type rhDAO was B8 U mg À1 protein.
Preparation of atelocollagen-plasmid complex. pEFBOSneo-mDAO (mouse DAO encoding plasmid vector) was constructed by subcloning a cDNA fragment of mouse DAO into the vector pEF-BOSneo. AteloGenet for local use (atelocollagen) (Koken, Tokyo, Japan) was used for in vivo transfection according to the manufacturer's instructions. Briefly, AteloGenet for local use was complexed with same volume of pEF-BOSneo-mDAO (1 mg ml
). The mixture was slowly rotated to mix the atelocollagen/plasmid solution at 4 1C for 20 min. From atelocollagen/plasmid mixture, 100 ml (containing 50 mg plasmid DNA) was used for in vivo intratumoral injection. The same was carried out with control plasmid (pEFBOSneo SE).
In vivo experiments. The 4-to 5-week-old female Sprague-Dawley rats (SD rats) (n ¼ 36) (Charles River, Shizuoka, Japan) were injected subcutaneously by inoculation of C6 glioma cells (5 Â 10 6 ) in 200 ml DMEM in the back region. At 6 days after C6 glioma injection, tumors of about 280 mm 3 were formed in all rats. AteloGenet/ plasmid intratumoral injection was carried out once 6 days after C6 inoculation. Rats were divided into seven groups (Table 1) : first group (negative control) (n ¼ 6) received phosphate-buffered saline, second group (mock group) (n ¼ 4) injected intratumorally with AteloGenet/ pEF-BOSneo SE and received D-serine treatment (90 mg kg À1 per day), third group (n ¼ 4) was injected intratumorally with pEF-BOSneo-mDAO without AteloGenet and received D-serine (90 mg kg À1 per day), fourth group (n ¼ 7) injected intratumorally with AteloGenet/ pEF-BOSneo-mDAO and received D-serine (90 mg kg À1 per day), fifth group (n ¼ 5) received 3BP (0.74 mg kg
per day) only, sixth group (n ¼ 6) injected intratumorally with AteloGenet/pEF-BOSneo-mDAO and received D-serine (90 mg kg À1 per day) and 3BP (0.74 mg kg À1 per day), and seventh group (n ¼ 4) received 3BP (1.85 mg kg À1 per day). Rats were injected intraperitoneally daily for 7 consecutive days with phosphate-buffered saline, 3BP and/ or D-serine. Tumor volume and body weight were measured before each injection. Survival, rat movement, rat weight and any complications of tumor or treatment were recorded every other day. Tumor volume was calculated as (length Â width 2 )/2. Animal skin was shaved over tumor area and then photographed using a digital camera. Kidney functions from all rats were evaluated by measuring serum creatinine and blood urea nitrogen. All in vivo experiments were approved by the Animal Experimentation Committee of The University of Tokushima.
Statistics
Results shown are mean ± s.e.m. of the values obtained from the indicated number of experiments. Differences between groups were analyzed by Student's t-test. Significant differences at Po0.05, Po0.01 and Po0.001 versus control are indicated by *, ** and ***, respectively. 
Results
Effect of OSED therapy on cellular viability and morphology Glioma and glioblastoma cell growth and viability are still a challenge that needs appropriate new modalities of treatment. Here, we investigated the effect of 3BP-( Figure 1a ) and DAO-induced effect on glioma cell viability. Our data revealed that serial 3BP treatment decreased markedly and significantly the percentage of C6 glioma viability in a dose-and time-dependent manner. C6/DAO viability decreased more significantly when adding D-serine (Figures 1c, e and g ).
Our data revealed that 15, 30 and 60 mM 3BP were significant in decreasing C6 and C6/DAO glioma viability with significant time-dependent effect. Combination of 3BP with 5 mM D-serine did not show a significant decrease in C6 glioma viability, whereas a combination of 3BP with 5 mM D-serine exhibited a significant decrease in the viability of C6/DAO cells. OSED effects on C6 and C6/DAO viability percentage remained significant with inducing a time-dependent progressive decreasing in glioma viability 48 and 72 h after treatment (Figures 1b-g ).
As shown in Figure 1h , upon treatment with 3BP, C6 glioma lost fibroblast morphology, for example, treatment with 60 mM 3BP caused fragmentation and loss of fibroblast morphology in all C6 and C6/DAO glioma cells within the first 24 h after treatment. C6 lost partially fibroblast shape with 30 mM 3BP and so was C6/DAO. C6/DAO showed more loss of fibroblast morphology on adding 5 mM D-serine. Treatment with 40 mM D-serine affected C6/DAO morphology more than C6.
As shown in Figures 2a-c , treatment of type-1 primary astrocytes with same doses and durations of 3BP and D-serine had a lesser effect on the viability of astrocytes. OSED treatment caused a lesser decrease in the viability of normal astrocytes compared with glioma cells at same doses and time course. Oxidative stress-energy depletion against glioma SM El Sayed et al novel mechanism of action in addition to the well-known mechanism of 3BP as an HK II inhibitor. As shown in Figure 3a , we found that 3BP induced a dose-dependent production of H 2 O 2 . Also, D-serine effect on producing H 2 O 2 in C6/DAO glioma was manifest, dose-dependent and more than its effect on C6. Our data revealed that when combining DAO and 3BP, H 2 O 2 production increased significantly.
Effects of antioxidants and pyruvate on 3BP-induced glioma death As shown in Figures 3a and b , to confirm the importance of 3BP-induced production of H 2 O 2 , we tested the ability of some antioxidants (reduced glutathione and N-acetyl-L-cysteine) and pyruvate (glycolysis downstream product) to rescue glioma cells against 3BP effects. Our data revealed that all previously mentioned agents significantly decreased 3BP-induced glioma cell death (Figure 3b ). Their protective effects were similar in C6 and C6/DAO cells.
OSED significantly decreased ATP levels in glioma cells
To confirm the potential of 3BP as an energy-depleting agent, we measured ATP levels in C6 and C6/DAO glioma 24 h after treatment with 3BP. 3BP significantly decreased ATP levels in glioma cells. 3BP effect was similar in both C6 and C6/DAO cells. Adding D-serine decreased ATP levels in C6/DAO more significantly than in C6 glioma cells (Figure 4a ).
Effect of 3BP on reducing equivalents in C6 cells
We assessed rapid effects of 3BP on reducing equivalent levels in C6 by assessing reductions in MTT signals in MTT reduction assay (3 h treatment) as folds of control untreated cells, which were assumed to be 1. As shown in Figure 4b , effect of 60 mM 3BP was significant (0. 
23
) did decrease the MTT signal considerably (0.31; Po0.001).
OSED effect on glioblastoma colony formation Because glioblastoma cells have the ability to form solid tumor masses, we investigated the clonogenic power of C6 glioma to form colonies. Plating efficiency (PE) calculated for C6 glioma cells was 33.52%. Plating efficiency for C6/ DAO cells was 26.56%. Our data revealed that OSED therapy had a powerful anticlonogenic effect on glioma (Figures 5a-c) . We investigated the clonogenic power of C6 glioma cells after treatment with 3BP concentrations (0, 15, 30 and 60 mM), (15 mM 3BP þ 5 mM D-serine and 30 mM 3BP þ 5 mM D-serine) and (5, 20 and 40 mM D-serine). The percentage clonogenic power in C6 glioma was (100%, 85.6%, 59.51% and 4.58%), (85.56% and 61.96%) and (96.39%, 85.89% and 39.95%), respectively. For C6/DAO, the same treatment revealed (100%, 87.8%, 62.39% and 3.86%), (60.67% and 6.18%) and (84.83%, 70.69% and 7.01%), respectively. Doses 30 and 60 mM 3BP were significant in decreasing clonogenic power of C6 and C6/DAO cells, whereas dose 15 mM 3BP was not significant. Adding 5 mM D-serine to 15 mM 3BP decreased clonogenic power significantly in C6/DAO more than that in C6 cells. Dose 5 mM D-serine decreased clonogenic power significantly in C6/DAO, but not in C6 cells. Dose 20 mM D-serine was more significant in C6/ DAO than in C6 cells.
As shown in Figures 6a-c, OSED therapy also suppressed anchorage-independent growth of glioma cells in a dose-dependent manner. For C6 glioma, which received same treatment as in clonogenic assay, the percentage of inhibition of anchorage-independent growth was (0%, 16.44%, 43.38% and 87.28%), (17.6% and 38.36%) and (3.72%, 31.87% and 51.37%), respectively, whereas for C6/DAO, it was (0%, 16.01%, 48.58% and 90.38%), (73.55% and 94.08%) and (26.04%, 59.19% and 98%), respectively. More significant results in decreasing anchorage-independent growth power were obtained when using 3BP and D-serine in the presence of DAO. 3BP was significant at doses 30 and 60 mM, but not at dose 15 mM. The effect of 15 mM 3BP became significant on C6/DAO (but not on C6) when combined with 5 mM D-serine. C6/DAO exhibited a more significant decrease in anchorage-independent growth than C6 when treated with 20 and 40 mM D-serine.
Mode of glioma cell death induced by 3BP As our data revealed that 3BP can induce significant glioma cell death, we investigated the mode of glioma cell death induced by 3BP. As shown in Figure 7 , 3BP induced Oxidative stress-energy depletion against glioma SM El Sayed et al both necrosis and apoptosis to glioma cells. 3BP-induced glioma cell death is dose-and time-dependent. At dose 30 mM 3BP (12 h after treatment), C6 glioma underwent apoptotic cell death (Annexin V positive population), which increased with time in addition to a small fraction of necro-apoptotic cell death (propidium iodide-and annexin V-positive population). At dose 60 mM 3BP (12 h after treatment), a major population of C6 glioma cells underwent necro-apoptotic death, whereas a minor population underwent apoptotic death. After 24 h with same treatment, total cell count markedly dropped with disappearance of the necro-apoptotic population and shift of major part of the unstained population to the apoptotic zone.
Effect of 3BP on rhDAO activity
We investigated the direct interaction between 3BP and DAO at the molecular level. The activity of purified wildtype rhDAO (Figure 8a ) increased when treated with serial concentrations of 3BP in micromolar range (Figure 8b ). Activation effects of rhDAO were observed when adding serial 3BP. Doses 15 and 30 mM 3BP were significant in inducing rhDAO activation (Po0.01). Oxidative stress-energy depletion against glioma SM El Sayed et al OSED significantly decreased viability in glioma three-dimensional culture models We established C6 and C6/DAO glioma spheroid threedimensional systems. Three-dimensional systems were reported to be much closer to clinical expression profiles than those seen in two-dimensional systems, and to have a greater power to predict clinical efficacies. 21 Our data revealed that OSED had a strong power to significantly decrease viability in glioma spheroids. The treatment with 30 mM 3BP, when combined with D-serine (5 mM), induced a similar cell death on C6/DAO glioma spheroids as that induced by 60 mM 3BP (Figure 9 ).
OSED significantly decreased glioma tumor growth in vivo. We investigated the growth rate of C6 glioma in an in vivo tumor model in SD rats. Our data revealed that all 36 rats injected with C6 showed tumor growth (100%). Study design was carried out as shown in Figure  11a , whereas treatment conditions were as shown in Table 1 .
Glioma tumor growth was rapid and progressive (tumor volume was 280±3.88 mm 3 6 days after C6 inoculation and reached more than 1800 mm 3 in control group by day 18) (Figures 11b and c) .
We also investigated the effect of atelocollagen (AteloGenet for local use) as an in vivo transfection agent for DAO gene therapy. Atelocollagen/mDAO/ D-serine significantly decreased glioma growth (Po0.05). Glioma growth was rapid and progressive in tumors receiving mDAO/D-serine without atelocollagen. A marked difference was found between DAO effect with and without complexing with atelocollagen. More significant decrease in glioma growth was achieved when atelocollagen/mDAO/D-serine was combined with 0.74 mg kg À1 3BP (Po0.01). Treatment using 0.74 mg kg À1 3BP alone was less effective in decreasing progression of glioma growth. Rats receiving 1.85 mg kg À1 3BP showed significantly decreased glioma growth (Po0.01).
Mock group showed progressive glioma growth similar to rats treated with mDAO without atelocollagen. No visible tumor could be seen in rats receiving OSED or receiving large dose 3BP (1.85 mg kg À1 ), where free shaved skin can be seen (Figure 11c ). In all, 50% of rats in the control group showed skin ulceration over the tumor as a sign of skin invasion by C6 glioma (direct metastatic spread) (Figure 11c ) as a complication of tumor. All other rats in all treatment groups did not show skin ulceration. All rats were alive throughout the experiment days. Rat feeding and movement were quite similar in all rats. Rat weight was progressively increasing similarly in all treatment groups as in the control group, with no significant difference among groups ( Table 2 ). The progress of weight gain in all rats was similar before start of treatment, during treatment and after treatment had stopped ( Table 2 ). The dose of D-serine used (90 mg kg
À1
) was safe with no nephrotoxicity as evidenced by normal kidney function tests in all rats, with no significant differences (Table 3) .
Discussion
Malignant gliomas are resistant to treatment. GBM is the most aggressive infiltrative form of primary brain tumors that invades and infiltrates surrounding brain. 1 Pediatric glioma response to conventional chemotherapy and radiotherapy is often poor and carries therapy-related morbidity to children. 24 Therefore, we need to establish a new line of treatment to gliomas and glioblastomas carrying effectiveness and lesser toxicities than conventional treatment.
In this study, we introduced OSED therapy as a new modality for glioma treatment. Oxidative stress in this study was exerted by DAO, which was a therapeutic protein that was easy to be produced by recombinant DNA technology. Recombinant DAO was reported to have potential anticancer effects, especially after being conjugated with polyethylene glycol. Its substrates (D-amino acids) exist very little under normal circumstances, making it possible to control H 2 O 2 production by controlling the dose of D-amino acids. 25 The aim of this study was to target HK II in C6 glioma using 3BP in micromolar concentrations. C6 glioma is an experimental model for studying GBM growth and invasion. 26 HK II seems to be an attractive therapeutic target in glioma. Glioma cell growth is related to glucose transport, which is closely associated with glucose metabolism as evidenced by the upregulation of glucose transporter-1 and HK, which is the initial enzyme for glycolysis pathway. 27 HK is 40% higher in glioma than the contralateral cerebral cortex. 28 Glioma cells become more resistant to apoptosis with stabilization of HK IImitochondria binding in glioma cells. 29 HK II has a preferred access to its substrate, Mg-ATP, that is synthesized within the mitochondria and then transported out. 30 HK II is associated more tightly with voltagedependent anion channels (VDAC) in tumor cells and this contributes significantly to the Warburg effect and forms the principle upon which 18-fluoro-deoxy glucose positron emission tomography cancer detection system is based. HK II-VDAC interaction prevents HK II inhibition by its product glucose-6-phosphate. 30 This indicates that the bioenergetics in cancer cells are different from normal cells and this can be an excellent target for cancer therapy.
According to our data, C6 gliomas are rapidly proliferating and have a high clonogenic power (formed Oxidative stress-energy depletion against glioma SM El Sayed et al colonies containing more than 50 cells in 8 days, which is a relatively short period) ( Figure 5 ). This may necessitate vast amount of energy. We noticed that the clonogenic power of C6 glioma cells was slightly stronger than that of C6/DAO cells, which needs further future investigation. Our data revealed that OSED therapy significantly decreased viability, proliferation power (Figure 1 ), clonogenic power ( Figure 5 ) and anchorage-independent growth of glioma cells in a dose-and time-dependent manner ( Figure 6 ). DAO sensitized glioma to 3BP, leading to massive glioma loss on combining D-serine with 3BP ( Figures 1, 5 and 6 ). HK is a preventive antioxidant, 31 and its inhibition by 3BP may disturb this protection in the glioma and enhances ROS-mediated damage. C6 glioma has a compromised redox state, decreased glutathione levels 32 and low glutathione peroxidase activity, 33 which confers sensitivity to oxidative stress therapy, especially when combined with another line of treatment as energy depletion using 3BP.
Our data revealed the safety of OSED therapy to the viability of normal astrocytes (Figures 2a-c) . Our data may be explained by the fact that HK II usually maintains very low expression levels in normal cells. 34 This may be explained in light of the report by Geschwind et al., 16 who reported that normal cells with normal mitochondria were less sensitive to inhibition of glycolysis as their intact mitochondria enable them to use alternative energy sources, such as fatty acids and amino acids to produce metabolic intermediates channeled to the mitochondrial tricarboxylic acid cycle for ATP production. 35 Interestingly, 3BP was reported to protect neurons of the hippocampus against excitotoxicity. 36 This together with our previous data confirms the safety of 3BP to normal brain cells and suggests 3BP strongly as a potent antiglioma agent with safe or less toxic effect on normal cell. Recently, high-dose D-serine proved effective clinically in the treatment of patients with schizophrenia. 37 DAO induced H 2 O 2 production (Figure 3a) , which is cytotoxic to glioma cells. 4, 17 We report in this study that in addition to the significant H 2 O 2 produced through DAO, 3BP also can induce more significant H 2 O 2 production (Figure 3a) . We report that 3BP caused the generation of H 2 O 2 on treating glioma cells. This may add a novel mechanism of action to 3BP and supports its broad range of anticancer effect.
Our data revealed that H 2 O 2 produced by 3BP was dose-dependent. 3BP-induced H 2 O 2 production was more in C6/DAO than C6 glioma when adding D-serine (DAO effect). 3BP-induced production of H 2 O 2 adds a novel link between 3BP and DAO and a novel characteristic to 3BP, which is shared also by conventional currently used chemotherapy agents, for example, vinblastine, doxorubicin, camptothecin and cisplatin. 25 Our data also revealed that the concurrent treatment of glioma cells, using 3BP with N-acetyl-L-cysteine, reduced glutathioneor pyruvate-protected glioma cells significantly from 3BP-induced glioma cell death (Figure 3b ). This also confirms significance of 3BP-induced H 2 O 2 production and its potential role in 3BP-induced glioma cell death.
Many mechanisms can explain the potential of 3BP to induce H 2 O 2 production. Based on our data, 3BP did decrease reducing equivalents levels (NADH and NADPH) (Figure 4b ), which reduces NAD(P)H redox state. Reduced NAD(P)H redox state was reported to cause H 2 O 2 production. 38 We suggest, based on other previous reports, more mechanisms that can explain how 3BP can induce H 2 O 2 production. As mitochondria-associated HK II activity plays an important role in preventing mitochondrial ROS generation, 31 inhibition of HK II by 3BP may be an explanatory mechanism for 3BP-induced H 2 O 2 production. The second possible mechanism to explain the potential of 3BP to generate H 2 O 2 is that mitochondria are the specialized redox-active organelles that control cell death associated with ROS production. 39 Mitochondrial electron transport chain is the major continuous source of cellular ROS. The production of ROS is dependent on the mitochondrial membrane potential. Mitochondrial membrane potential is dysregulated upon treatment with 3BP, 19 as 3BP targets HK II-VDAC. Dysregulation of mitochondrial membrane potential is reported to be a cause for H 2 O 2 production. 40 In addition to that, 3BP was reported to induce oxidative stress, 41 which may be explained in light of our data (Figures 3a and b) to result from H 2 O 2 generation. The third possible mechanism to explain 3BP-induced H 2 O 2 production comes from the fact that cancer cells have a defect in mitochondrial respiration, leading to increased steady-state levels of O 2 À and ROS. Glucose metabolism usually increases to compensate for this defect. 42 As 3BP inhibits glucose consumption, 19 this may induce increased H 2 O 2 generation. The fourth possible mechanism for 3BP-induced H 2 O 2 production may be through conversion of 3BP-induced O 2 À (ref. 43 ) into H 2 O 2 through the activity of superoxide dismutase enzyme. 3 Figure 10a summarizes suggested mechanisms for 3BP-induced H 2 O 2 production. H 2 O 2 was reported to induce ATP hydrolysis, leading to decreased intracellular ATP and lactate in C6 glioma cells together with increased intracellular acidosis. 44 H 2 O 2 was reported to inhibit the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH), leading to further energy depletion. 45 This may suggest that as DAO has the potential to generate H 2 O 2 in its reactions, DAO may have an indirect antiglycolytic effect through inhibiting GAPDH. GAPDH is an important therapeutic target in glioblastoma as GAPDH mRNA expression is markedly increased in human glioblastoma tissues and its inhibition decreased viability and proliferation in C6 and RG2 rat glioma cell lines. 46 According to our data, 3BP induced significant dosedependent energy depletion in glioma cells (Figure 4a ). 3BP-induced energy depletion was similar in C6 and (Figure 4b ). Those reductions reflect the levels of reducing equivalents (NADH and NADPH). 3BP depleted reducing equivalents in a dose-dependent manner. Our data agreed with the report of Ihrlund et al., 19 who got similar results with the human colorectal carcinoma cell line, HCT116 cells. In our data, all the tested 3BP concentrations were significant in reducing glioma-reducing equivalents. This gives idea about the energy depletion that happens on treating glioma cells with 3BP. This metabolic derangement selectively deprived glioma cells from NADH. This may cause a subsequent decrease in energy supply that comes through malate-aspartate shuttle and glycerophosphate shuttle in which NADH is oxidized to give three ATP and two ATP, respectively. Low NAD(P)H was reported to inhibit lactate dehydrogenase enzyme, which leads to a further inhibition of glycolytic ATP production. 47 This may decrease survival and growth of glioma cells dramatically.
OSED therapy suggests the possibility of glycolysis double inhibition, that is, OSED causes inhibition of two enzymes of glycolysis pathway. GAPDH can be inhibited by H 2 O 2 , 45 which is produced through 3BP and DAO in addition to 3BP-induced HK II inhibition. This may explain the potential of OSED therapy as antiglioma treatment (Figure 10b) .
We also investigated the type of glioma cell death on treatment with 3BP. Our data revealed that 3BP induced both necrotic and apoptotic death in glioma cells (Figure 7 ). This gives a big advantage to 3BP as a suggested broad-spectrum anticancer agent and makes 3BP better than anticancer therapeutics inducing one mode of cancer cell death.
In light of our data that 3BP induced ATP and NADH depletion (Figures 4a and b) , 3BP-induced glioma cell apoptosis may be further explained in light of previous reports that cancer cells which utilize almost exclusively glucose via glycolysis and oxidative phosphorylation die from ATP and NADH depletion as a consequence of the release of apoptosis-inducing factor from the mitochondria to the cytosol. 3BP-induced necrotic cell death may result from the alkylating effect of 3BP. Alkylating agents were reported to induce a regulated form of necrotic cell death. 48 The rate of apoptosis induced by some cancer therapeutics showed a little correlation with suppression of clonogenic ability of cancer cells, which results in tumor recurrence. Therefore, the preferred anticancer therapy is a treatment (or treatment combinations) that promotes the necrotic form of cell death. In some currently used anticancer treatments, doxorubicin induces necrotic cell death to cancer cells and induces also H 2 O 2 production. 49 OSED therapy-induced necrosis shares this property with some currently used chemotherapeutics. According to our data (Figure 7 ), in addition to 3BP-induced necrotic glioma cell death, 3BP has the potential to induce apoptotic cell death in glioma cells, which widens its range in killing cancer cells.
Our data revealed that purified wild-type rhDAO (Figure 8a ) underwent activation effects when treated with serial concentrations of 3BP in micromolar range (Figure 8b ). Activation effects were significant on using 15 and 30 mM 3BP. This type of activation may be explained as a non-essential activator that acts as a Abbreviations: OSED, oxidative stress-energy depletion; SD, Sprague-Dawley. deinhibitor (antiinhibitor), in which the activator competes with the inhibitor for the inhibitor site. 50 3BP (Figure 1a) is a structural analog of pyruvate (end product of DAO reaction with D-amino acids). 3BP can be considered to compete with pyruvate for the inhibitor site. Antiglioma effect of D-serine and its combinatory effect with 3BP may be further explained in light of the data by Chung et al., 51 who reported that D-serine is metabolized by DAO to produce hydroxypyruvate, which is toxic to glioma cells. Hydroxypyruvate is a structural analog to 3BP and exerted its antiglioma effects in submillimolar concentrations. We established multicellular tumor spheroids for C6 and C6/DAO glioma as a three-dimensional culture model. Multicellular tumor spheroids resemble avascular tumor nodules/micrometastases or intervascular regions of large solid tumors with respect to micromilieu, volume growth kinetics and some histomorphological features. 21 Our data revealed that OSED treatment significantly reduced multicellular tumor spheroids' viability ( Figure 9 ). OSED effect was dose-dependent. 3BP effect was similar in both C6 and C6/DAO spheroids. The effect of D-serine alone was stronger and more significant on C6/DAO than on C6 glioma spheroids. Significant combinatory effects were observed when adding D-serine to 3BP.
Suggested mechanisms for antiglioma effect of 3BP (Figure 10b ) include depletion of ATP and reducing equivalents in cancer cells (Figures 4a and b) , destabilizing mitochondrial membrane potential and inhibition of HK II. 19 HK II was reported to be a novel mediator of the antiapoptotic effects of growth factors and Akt 52 and a preventive antioxidant. 31 3BP induces ROS production in the form of H 2 O 2 ( Figure 3a ) and superoxide anion (O 2 À ). 43 As 3BP is a lactate analog, its uptake is easy via lactate transporters, which are overexpressed in tumor cells. 8 Moreover, targeting HK-VDAC by 3BP was reported to cause dissociation of HK II enzyme from the permeability transition pore complex (PTPC) of mitochondrial membrane, leading to opening of the PTPC. Opening of PTPC may lead to mitochondrial membrane permeabilization, which leads to cytochrome c release to the cytosol. 53 Based on our data (Figure 3a) , 3BP induced H 2 O 2 production. H 2 O 2 production was reported to be another mechanism to explain 3BP-induced PTPC opening. 54 3BP leaves normal cells alone as they have either very low levels of monocarboxylic acid transporters or no monocarboxylic acid transporters that are required to transport 3BP into the cell.
To investigate OSED effect on glioma growth in an in vivo tumor model, we injected C6 glioma cells subcutaneously in the back region of SD rats (Figure 11a ). We report here that C6 glioma subcutaneous tumors in SD rats continued to grow progressively to gain a large size reaching about 1800 mm 3 (Figures 11b and c) at day 18 after C6 inoculation. Subcutaneous model for glioma has the advantage of enabling easy measurement of the volume of the tumor without killing the rats and the easy measurement of tumor volume at serial time points. Another advantage of this model is the rapid growth of C6 glioma at the subcutaneous site, that is, size of subcutaneous glioma tumors increased sixfolds between 6th and 18th day after C6 inoculation. More interesting is the report by Watanabe et al., 55 who reported that there were no differences between the intracerebral and subcutaneous C6 glioma tumors in terms of histological structure, including cellularity and pseudopalisading, which may encourage utilization of this subcutaneous glioma model. 55 Our data revealed that OSED significantly decreased the growth rate of C6 glioma in an in vivo tumor model in SD rats. We investigated the effect of atelocollagen as an in vivo transfection agent for DAO gene therapy. Our data revealed that atelocollagen (AteloGenet for local use) was appropriate for in vivo transfection of pEF-BOSneomDAO plasmid in a C6 glioma subcutaneous tumor model in SD rats. DAO gene therapy alone (with atelocollagen) significantly slowed tumor increase in size (Figures 11b  and c) , that is, atelocollagen/mDAO/D-serine significantly decreased glioma growth (Po0.05). Glioma growth was rapid and progressive in tumors receiving mDAO without atelocollagen (Figures 11b and c) . 3BP exerted a dosedependent effect in decreasing glioma growth. 3BP at dose 0.74 mg kg À1 was less effective in slowing progression of glioma growth. More significant decrease in glioma growth was achieved when 3BP (0.74 mg kg À1 per day) was combined with atelocollagen/mDAO/D-serine (Po0.01). 3BP at a dose of 1.85 mg kg À1 exerted a potent significant antiglioma effect (Po0.01). Glioma tumors did not significantly increase in size with that dose of 3BP or with combinatory treatment even after stopping treatment. Our data agreed with the previous report by Young Ko et al., 56 who reported that hepatoma tumors were eradicated (19 out of 19 advanced cancers) using 1.85 mg kg À1 (1 ml of 2 mM 3BP/180 g) in SD rats. When treatment stopped, no further significant increase in glioma growth was observed in treatment groups receiving DAO/atelocollagen gene therapy, DAO/atelocollagen gene therapy combined with 0.74 mg kg À1 3BP or in rats receiving 1.85 mg kg
À1
3BP alone, which reflected loss of glioma growth power on OSED therapy (Figures 11b and c) . OSED was quite safe on animal's general health as evidenced by survival of rats throughout experiment days, with no movement abnormalities, no ulcers (direct metastatic invasion), good feeding power, progressive weight gain (Table 2) , normal kidney function tests, which were similar in all rats, with no significant differences between control and treatment groups (Table 3 ).
In conclusion, OSED therapy is a suggested new modality for glioma treatment in which both oxidative stress and energy depletion occurred through both DAO and 3BP. DAO enhanced oxidative stress and energy-depleting effect of 3BP. Our data added a novel mechanism of action of 3BP, which is H 2 O 2 production, as some currently used chemotherapeutics. OSED therapy seems safe and less toxic towards normal cells. We hope that OSED therapy can be a new promising line of treatment to glioma and glioblastoma.
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